Chemotherapy toxicity in elderly women with ovarian, primary peritoneal or fallopian tube cancer
Principal Investigator
Vivian vonGruenigen, MD
Status
Terminated
Date Opened To Accrual
August 15 2011
Date Closed to Accrual
June 04 2014
Date of Study Termination
January 28 2023
Disease Site
Gynecologic [GY]
Ovarian
Phase
III
Developmental Therapeutics
No
Primary Objective
To determine whether the score on IADL obtained prior to treatment is associated with the ability of patients to complete four cycles of chemotherapy without dose reduction or a more than 7-day delay.
To estimate by regimen the percentage of patients who are able to complete four cycles of chemotherapy regardless of dose reductions and delays.
To compare actual and calculated carboplatin AUC in this patient population.
Patient Population
Patients who initiate one of the study chemotherapy regimens.
Target Accrual
317
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.